Invezz

Liminatus Pharma (LIMN)

NasdaqMarket Closed

Liminatus Pharma, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, with a development pipeline aimed at cancers that remain difficult to treat with existing therapies. Its Class A common stock gives investors exposure to an early-stage drug developer whose value is tied primarily to clinical progress, regulatory outcomes, financing capacity, and the commercial potential of its experimental medicines.

The company’s lead disclosed programme is a Guanylyl Cyclase C, or GCC, vaccine being evaluated in Phase II clinical trials. GCC is a marker expressed in several gastrointestinal cancers, and Liminatus is studying whether an immune-based approach can help target malignancies such as colorectal, pancreatic, gastric, and oesophageal cancers. These are large oncology indications where improved treatment options are still needed, particularly for patients whose disease is advanced or resistant to standard care.

Liminatus is also developing a next-generation CD47 immune checkpoint inhibitor. CD47 is often described as a “don’t eat me” signal used by cancer cells to avoid clearance by the immune system. Blocking this pathway is a recognised strategy in cancer immunotherapy, but some anti-CD47 antibodies can bind to red blood cells and platelets, raising safety concerns such as anaemia, thrombocytopenia, and haemolysis. Liminatus says its CD47 monoclonal antibody is designed to bind preferentially to immune cells rather than red blood cells or platelets, with the aim of improving tolerability. This candidate is in late preclinical development, meaning it has not yet reached human efficacy testing.

5.16USD
−0.47(-8.35%)

Last updated

Market Cap
$7,501,812
P/E
P/FCF
P/S
Enterprise Value
Sector
Materials
Industry
Biological Products, Except Diagnostic Substances
Address
12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Market Cap
$7,501,812
Enterprise Value
P/E
P/B
P/S
EV / EBITDA
EV / Sales
EPS
Dividend Yield
P/FCF
P/CF
Free Cash Flow
ROE
ROA
Debt / Equity
Current Ratio
Quick Ratio
Cash
Avg Volume
Fundamentals Snapshot Price

Financial statements are not available for this listing.

KindFilingDateLink
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index10-Q — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar indexSCHEDULE 13G — Liminatus Pharma, Inc.View Filing
edgar indexSCHEDULE 13D/A — Liminatus Pharma, Inc.View Filing
edgar index4 — Liminatus Pharma, Inc.View Filing
edgar indexDEF 14A — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar indexSCHEDULE 13G/A — Liminatus Pharma, Inc.View Filing
edgar index3 — Liminatus Pharma, Inc.View Filing
edgar index4 — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
form 3Form 3 — Ewon Comfortech Co., Ltd.View Filing
form 4Form 4 — Kim ChrisView Filing
form 4Form 4 — Valetudo Therapeutics LLCView Filing
form 4Form 4 — Valetudo Therapeutics LLCView Filing
form 4Form 4 — Kim ChrisView Filing
edgar indexPRE 14A — Liminatus Pharma, Inc.View Filing
edgar indexS-1 — Liminatus Pharma, Inc.View Filing
form 4Form 4 — Valetudo Therapeutics LLCView Filing
form 4Form 4 — Kim ChrisView Filing
edgar indexD — Liminatus Pharma, Inc.View Filing
edgar index424B3 — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar index10-Q — Liminatus Pharma, Inc.View Filing
edgar index10-K — Liminatus Pharma, Inc.View Filing
ten k section10-K — businessView Filing
ten k section10-K — mdaView Filing
ten k section10-K — risk_factorsView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar indexSCHEDULE 13G — Liminatus Pharma, Inc.View Filing
edgar index424B4 — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
eight k text8-K — 8-KView Filing
edgar indexEFFECT — Liminatus Pharma, Inc.View Filing
edgar indexS-1 — Liminatus Pharma, Inc.View Filing
edgar indexCORRESP — Liminatus Pharma, Inc.View Filing
edgar indexCORRESP — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar indexUPLOAD — Liminatus Pharma, Inc.View Filing
edgar indexDRS — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar index10-Q — Liminatus Pharma, Inc.View Filing
edgar index10-Q — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar indexNT 10-Q — Liminatus Pharma, Inc.View Filing
edgar index3 — Liminatus Pharma, Inc.View Filing
form 3Form 3 — Iris Acquisition Holdings LLCView Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar index424B3 — Liminatus Pharma, Inc.View Filing
edgar indexEFFECT — Liminatus Pharma, Inc.View Filing
edgar indexCORRESP — Liminatus Pharma, Inc.View Filing
edgar indexS-1/A — Liminatus Pharma, Inc.View Filing
edgar indexCORRESP — Liminatus Pharma, Inc.View Filing
edgar index3 — Liminatus Pharma, Inc.View Filing
edgar index3 — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar indexUPLOAD — Liminatus Pharma, Inc.View Filing
edgar index8-K — Liminatus Pharma, Inc.View Filing
edgar indexSCHEDULE 13G — Liminatus Pharma, Inc.View Filing
edgar index3 — Liminatus Pharma, Inc.View Filing